Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis
- The FDA decision follows the Company’s Fast Track designation request for lanifibranor in NASH with compensated cirrhosis filed in August 2021
Daix (France), Long Island City (New York, United States), September 21, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has decided that the Fast Track designation previously granted to lanifibranor in NASH encompasses the treatment of NASH patients with compensated cirrhosis.
This decision follows a Fast Track designation request for lanifibranor in NASH with compensated cirrhosis filed by Inventiva with the FDA in August 2021. Previously, the FDA had granted both Fast Track and Breakthrough Therapy designations to lanifibranor for the treatment of NASH in September 2019 and October 2020, respectively.
The FDA’s dedicated Fast Track program is designed to facilitate the development and expedite the review and potential approval of drug candidates demonstrating the capacity to treat serious conditions and fill significant unmet medical needs.
Pierre Broqua, Ph.D., Chief Scientific Officer and cofounder of Inventiva, commented: “We are delighted to have a Fast Track designation for lanifibranor in NASH that extends to the treatment of NASH with compensated cirrhosis, a very severe stage of the disease where patients are in urgent need of treatment. The FDA decision does not only recognize this urgency but also the potential of lanifibranor to address this crucial unmet medical need. This news reinforces our confidence in the unique mechanism of action of our lead drug candidate and confirms our determination to accelerate the development of lanifibranor in its pivotal phase.”
NASH with compensated cirrhosis represents a serious stage of the disease and is becoming the leading cause for liver transplantation, which today represents the only available treatment option for patients who have progressed to end-stage NASH. There is thus an urgent need to develop pharmacological therapies to slow down or halt the progression towards NASH with compensated cirrhosis for NASH patients who are at an increased risk of liver-related morbidity and mortality.
Given the broad range of activity of lanifibranor as a pan-PPAR agonist on multiple features of NASH, including beneficial effects on metabolism, inflammation, ballooning, fibrosis and vascular manifestations, Inventiva believes that there is a strong rationale to evaluate the efficacy of lanifibranor in NASH patients with compensated cirrhosis.
About Fast Track designation1
Fast track is a process designed to facilitate the development and expedite the review and potential approval of drug candidates to treat serious, life-threatening conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier.
Determining whether a condition is serious is a matter of judgment, but generally is based on whether the drug will have an impact on factors such as survival, day-to-day functioning, or the likelihood that the condition, if left untreated, will progress from a less severe condition to a more serious one.
Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy. Any drug being developed to treat or prevent a condition with no current therapy is obviously directed at an unmet need. If there are available therapies, a Fast Track drug must show some advantage over available therapy, which is assessed against a pre-defined set of criteria.
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.
Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of preclinical programs.
Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained both FDA Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH. Lanifibranor is currently being evaluated in a pivotal Phase III clinical trial.
Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients in 2019 and received both FDA Fast Track and Rare Paediatric Disease designation for odiparcil in MPS VI.
In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.
The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.
Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.
VP of Global External Affairs
+1 240 620 9175
Yannick Tetzlaff /
Tristan Roquet Montegon /
+33 1 53 96 83 83
|Westwicke, an ICR Company|
Patricia L. Bank
+1 415 513 1284
This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva’s clinical trials, clinical development plans and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to the potential benefits Inventiva may realize fromFast Track designation granted to lanifibranor, its ability to accelerate the development of lanifibranor, or that lanifibranor will receive the necessary regulatory approvals. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the Universal Registration Document for the year ended December 31, 2020 filed with the Autorité des Marchés Financiers on March 15, 2021, the Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 15, 2021, Amendment No. 1 to the Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 24, 2021, as well as the half-year financial report for the six months ended June 30, 2021 for additional information in relation to such factors, risks and uncertainties.
Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nokia selected by T-2 Slovenia in five-year 5G deal as sole supplier18.10.2021 10:00:00 CEST | Press release
Press Release Nokia selected by T-2 Slovenia in five-year 5G deal as sole supplier Nokia to expand T-2’s Single RAN footprint and introduce enhanced 5G services across the country 18 October 2021 Espoo, Finland – Nokia today announced that it has been selected as the sole vendor by Slovenia’s T-2 in a five-year deal to supply equipment from its comprehensive AirScale 5G portfolio. The new deal will see Nokia upgrade T-2’s existing Single RAN radio footprint as well as introduce enhanced 5G new radio (NR) services. The project is expected to deliver ultra-fast, low-latency, and high-capacity 5G connectivity delivering superior coverage to businesses and consumers alike. Nokia will provide equipment from its latest AirScale radio portfolio, all powered by Nokia's energy-efficient ReefShark System-on-Chip technology. This includes 5G RAN, AirScale base stations, and Nokia AirScale radio access products including its Single RAN portfolio for both indoor and outdoor coverage. These solution
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme18.10.2021 09:24:27 CEST | Press release
Company Announcement No. 51/2021 Copenhagen, 18 October 2021 Transactions in connection with share buy-back programme On 10 March 2021, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 600 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 28 February 2022. The following transactions have been executed from 11 October to 15 October 2021: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated, last announcement2,892,365366,515,65211 October 202117,481129.962,271,75912 October 20219,122
KALLELSE TILL EXTRA BOLAGSSTÄMMA I HOYLU AB (PUBL)18.10.2021 08:35:00 CEST | Pressemelding
KALLELSE TILL EXTRA BOLAGSSTÄMMA I HOYLU AB (PUBL) Aktieägarna i Hoylu AB (publ), org. nr 559084-6381 ("Bolaget") kallas härmed till Bolagets extra bolagsstämma måndagen den 22 november 2021, kl. 10.00 hos Eversheds Sutherland Advokatbyrå på Strandvägen 1 i Stockholm. Inregistrering inleds kl. 09.45. INFORMATION MED ANLEDNING AV COVID-19 Med anledning av COVID-19 kommer Bolaget att vidta vissa försiktighetsåtgärder inför extra bolagsstämman. För att minska risken för smittspridning kommer ingen förtäring eller dryck att erbjudas. Styrelsemedlemmar och Bolagets ledning kommer i möjligaste mån att närvara via elektronisk uppkoppling. Aktieägarna har möjlighet att närvara via ombud. DELTAGANDE En aktieägare som vill delta på extra bolagsstämman ska: vara införd i den av Euroclear Sweden AB förda aktieboken senast fredagen den 12 november 2021, ochanmäla sitt deltagande senast tisdagen den 16 november 2021, helst före kl. 16.00. Anmälan att delta på extra bolagsstämman ska ske via e-post t
NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING IN HOYLU AB (PUBL)18.10.2021 08:35:00 CEST | Press release
N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in Hoylu AB (publ), and in case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING IN HOYLU AB (PUBL) The shareholders of Hoylu AB (publ), reg. no 559084-6381 (the “Company”) are hereby summoned to attend the extraordinary general meeting held at 10:00 (CET) on Monday 22 November 2021 at the premises of Eversheds Sutherland Advokatbyrå located at Strandvägen 1, Stockholm, Sweden. Registration begins at 09:45 (CET). INFORMATION RELATED TO THE CORONA VIRUS To minimise the risk of spreading the corona virus, no food and beverages will be served at the EGM. Participation of board members and company management will be restricted to online where possible. Shareholders who so desire can attend via a representative. NOTIFICATION OF PARTICIPATION ETC. Share
Hoylu AB (publ) carries out a SEK 19.2 million convertible loan notes issue and calls for EGM to resolve on a SEK 0.9 million convertible loan notes issue to board members18.10.2021 08:30:00 CEST | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. The Board of Directors of Hoylu AB (publ) (“Hoylu” or the “Company”) has, with support of authorization granted by the annual general meeting on 21 May 2021, carried out a directed issue of convertible loan notes corresponding to a value of SEK 19.2 million. Furthermore, the Company’s shareholder Fougner Invest AS hasproposed that the Company’s extraordinary general meeting resolves on a directed issue of convertible loan notes of SEK 0.9 million towards COO Truls Baklid and CFO Karl Wiersholm and the board members Johan Lindqvist and Hans Othar Blix.Noticeconvening the extraord
Reminder: Program for the publication of Yara International ASA third quarter results 202118.10.2021 08:00:00 CEST | Press release
The Yara International ASA third quarter 2021 results will be published on Wednesday20 October 2021at08:00 CEST. An on-line presentation will be held at 12:00 CEST, hosted by Yara President and CEO Svein Tore Holsether. The presentation will be held in English. The report, presentation and webcast will be available at the above mentioned times at: yara.com/investor-relations/latest-quarterly-report/ There will also be a conference call at 13:00 CEST the same day with an opportunity to ask questions to Yara’s management. Please use this link for online registration for the conference call: http://emea.directeventreg.com/registration/5886579 Participants must register in advance of the conference using the link provided. Upon registering, each participant will be provided with participant dial-in numbers, Direct Event passcode and unique registrant ID.In the 10 minutes prior to call start time, participants will need to use the conference access information provided in the email received
PRESS RELEASE: Bigben finalizes the acquisition of Metronic18.10.2021 07:45:00 CEST | Press release
Press release Lesquin, 18 October 2021, 8:00 hrs Bigben finalizes the acquisition of Metronic (Home Digital Lifebusiness unit of HF Company) Bigben announces the completion of the acquisition of METRONIC within its Audio/Telco Division. METRONIC is the European leader in image processing with a strong position in connected audio-video. Founded in 1987 by Yves Bouget, METRONIC, a recognized player in its sector, designs and distributes innovative products for broadcasting and receiving images in the home (TV and audio accessories, amplifiers, decoders, connectors, headsets, speakers, etc.) as well as telephone accessories and audio products. METRONIC brand products are distributed through a variety of channels, notably through the largest national retailers in each country. METRONIC has offices in France (Tours), Spain and Italy, and employs approximately 90 people. Including its subsidiaries, METRONIC posted sales of 24 M€ and EBITDA of 1.9 M€ as of December 31, 2020. Many synergies be